Atlas Trials

Ribociclib, Tucatinib, and Trastuzumab for the Treatment of HER2 Positive Breast Cancer

Clinical trial NCT05319873 · ACTIVE_NOT_RECRUITING

Trial details

NCT number
NCT05319873
Sponsor
Jonsson Comprehensive Cancer Center
Status
ACTIVE_NOT_RECRUITING
Phase
Phase 1, Phase 2
Study type
INTERVENTIONAL
Anatomic Stage II Breast Cancer AJCC v8Anatomic Stage IIA Breast Cancer AJCC v8Anatomic Stage IIB Breast Cancer AJCC v8Anatomic Stage III Breast Cancer AJCC v8Anatomic Stage IIIA Breast Cancer AJCC v8Anatomic Stage IIIB Breast Cancer AJCC v8Anatomic Stage IIIC Breast Cancer AJCC v8Anatomic Stage IV Breast Cancer AJCC v8Invasive Breast CarcinomaLocally Advanced HER2-Positive Breast CarcinomaMetastatic HER2-Positive Breast CarcinomaPrognostic Stage IB Breast Cancer AJCC v8
Start date
2022-04-07
Primary completion
2027-04-01
Enrollment
18

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.